Advice

following an abbreviated submission:

leuprorelin acetate (Prostap®) is accepted for use within NHSScotland.

Indication under review: as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.

Leuprorelin offers an additional treatment choice in the therapeutic class of gonadotropin-releasing hormone (GnRH) analogues for this indication.

Download detailed advice725KB (PDF)

Download

Medicine details

Medicine name:
leuprorelin acetate (Prostap DCS)
SMC ID:
SMC2319
Indication:

As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement). In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.

Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Status
Accepted
Date advice published
08 February 2021